fbpx
Brian McMahon

About Brian McMahon

Brian McMahon is a four-time cancer caregiver and the founder of SparkCures, a multiple myeloma clinical trial finder tool.

Clinical Trial: Daratumumab, Ixazomib, and Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma (DeRIVE)

A phase II study is open evaluating how well daratumumab, ixazomib, and dexamethasone work with or without bortezomib in treating patients with newly diagnosed multiple myeloma. Please not that for one of the patient groups, it will use two different types of proteasome inhibitors in consecutive order.  Open-Label: Patients and their doctors will know both the [...]

Read More

Clinical Trial: Using a Vaccine PVX-410 with Citarinostat +/- Lenalidomide for Smoldering Multiple Myeloma

A Phase I study of a vaccine called PVX-410 for patients with moderate/high risk Smoldering Multiple Myeloma is open. PVX-410 is a multi-peptide vaccine that helps promote the immune system to fight myeloma. The FDA (U.S. Food and Drug Administration) has not yet approved PVX-410 as a treatment for any disease. The study will be testing the appropriate [...]

Read More

Clinical Trial: Testing a BCMA Monoclonal Antibody (SEA-BCMA) With a T Cell Therapy (ACTR087) for Relapsed or Refractory Multiple Myeloma Patients

A new Phase I study is open combining a BCMA monoclonal antibody with a T cell antibody. While the field of BCMA monoclonal antibodies is getting more crowded, Seattle Genetics designed one to more specifically target myeloma cells. Their antibody is made using the company's  proprietary Sugar Engineered Antibody (SEA) technology, which adds sugar molecules to [...]

Read More

Clinical Trial: Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

This trial is evaluating dose escalation and expansion of a new Janssen drug called JNJ-64007957. JNJ-64007957 is a bi-specific antibody, a new kind of drug which has two targets. One of its targets is BCMA, a protein found on myeloma cells, and the other is CD3, which is found on our T cells. The drug joins your [...]

Read More

Sparking a Cure for Multiple Myeloma: Brian McMahon, Founder of SparkCures

Brian McMahon, 4-time cancer caregiver, and founder of SparkCures is from Pittsburgh, Pennyslvania. He was recently featured in Conquer Magazine.    Read more about his story in the link below:    My mother was not a typical patient with cancer. She was an oncology nurse with more than 30 years of experience and a string of [...]

Read More

The Right to Try Act and What It Means for Myeloma Patients

The new Right to Try Act was signed into law on May 30, 2018. This act builds on the foundation of the governments Expanded Access programs, that we previously wrote about here. Previously, if a patient with a terminal illness was seeking an experimental treatment under the Expanded Access program, their doctor was required to [...]

Read More

Antibody Drug Conjugates As Immunotherapy In Myeloma

Antibody Drug Conjugates (ADCs) are a new type of immunotherapy that is being developed and tested in multiple myeloma. To better understand how and why ADCs work, we first need to look at some different classifications of drugs that have traditionally been used to treat multiple myeloma. Chemotherapy Chemotherapy has been used to treat multiple [...]

Read More

Clinical Trial: Phase 1 Study of the Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma

This is a Phase 1, open-label, single dose, dose escalation safety study evaluating a CAR-T Cell product in patients with Relapsed or Refractory Myeloma. One of the goals of this study is to help determine the safest dose of this therapy, so participants will be separated into groups that will receive different dosages of CAR2 [...]

Read More

Clinical Trial: Phase II Antibody Drug Conjugate Trial for Relapsed/Refractory Myeloma Patients

This is a Phase 2 study evaluating a new antibody drug conjugate treatment for patients with relapsed/refractory multiple myeloma. This trial is also: Open-Label:Patients and their doctors will know both the treatment and the dose that they will be receiving. Randomized: Participants will be divided into different dosage groups randomly. Multi-Dose:This trial is testing different [...]

Read More

New Jersey: Hackensack Meridian Health’s New Myeloma Institute

The team at Hackensack Meridian Health, part of New Jersey’s largest and most comprehensive healthcare network, recently announced the opening of the Institute for Multiple Myeloma. The Institute will be located in a state-of-the art research facility at the Hackensack Meridian Health Interprofessional Health Sciences Campus in Nutley and Clifton, NJ, and led by founding [...]

Read More

SparkCures New Clinical Trial Patient Worksheet Guides Through Trial Exploration

At SparkCures, we are dedicated to helping myeloma patients discover their clinical trial options. We know that navigating the ever changing clinical trial landscape is difficult, and we want to make this process as easy as possible for our patients. With this goal in mind, we have created a Clinical Trial Patient Worksheet to help [...]

Read More

Clinical Trial: Study of CD8+ anti-BCMA CAR T-cells in Patients with Multiple Myeloma

This is a Phase 1 ascending dose study evaluating a new CAR-T cell therapy called Descartes-08. This trial is sponsored by Cartesian Therapeutics.  In this trial, your own T-cells are removed from your body and modified by adding a Chimeric Antigen Receptor, making them CAR-T cells. These CAR-T cells are then designed to target the [...]

Read More

SparkCures Announces New Updates to Improve Clinical Trial Matching

At SparkCures, our goal is to help our patients find and understand their potential clinical trial options. We are constantly working to improve our matching technology so that we can provide you with the most accurate results. One of the ways we achieve this is by allowing you to input your most recent lab values into [...]

Read More

Clinical Trial: Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma (MASTER)

A new study for newly diagnosed myeloma patients is opening with the goal to inducing deep remissions using a four drug combination as initial treatment. This Phase 2 study will have two arms. Both groups will begin therapy with dexamethasone, lenalidomide (Revlimid), daratumumab (Darzalex), and carfilzomib (Kyprolis). The KRdD combination will be given in four [...]

Read More

Clinical Trial: New Inhibitor Tested for Patients With Relapsed or Refractory Multiple Myeloma

A phase I clinical trial is open testing AMG 176 in patients with relapsed or refractory multiple myeloma (as well as patients with acute myeloid leukemia).  AMG 176 is an MCL-1 inhibitor (myeloid cell leukemia-1) that can prevent cancer cells from creating proteins to protect itself, and can cause cell death. The protein encoded by the [...]

Read More

Clinical Trial: Study of Bromodomain and Extra-Terminal Protein (BET) Inhibitor for Advanced Multiple Myeloma

A new inhibitor is being combined with daratumumab for a Phase I multi-center, global study. R06870810 is a Bromodomain and Extra-Terminal (BET) Protein inhibitor, a new kind of drug that may inhibit the expression of genes that help myeloma cells to grow, possibly inhibiting tumor growth.  There are currently two planned phases: dose escalation and expansion. [...]

Read More

Clinical Trial: Evaluating the Safety and Efficacy of KITE-585 in Subjects With Relapsed/Refractory Multiple Myeloma

A Phase I study is open evaluating the safety of a CAR T-cell treatment called KITE-585 for patients with relapsed/refractory myeloma. KITE-585 is an autologous engineered CAR T-cell product targeting a protein commonly found on myeloma cells called BCMA. Patients eligible for this trial will have their white blood cells collected via apheresis, and these [...]

Read More

Clinical Trial: Phase 1 BCMA-CD3 Bispecific Antibody for Relapsed/Refractory Myeloma Patients

A new Phase 1 study is open to test different doses of a new bispecific antibody treatment for patients with relapsed/refractory multiple myeloma. The new drug (called PF-06863135) is a bispecific antibody, which is a new treatment designed to have two different targets. In this case, PF-06863135 targets CD3, which is found on T Cells, [...]

Read More

Clinical Trials and Compassionate Use in Multiple Myeloma

Every myeloma treatment available, even our first line therapies, began as a clinical trial. There are so many promising treatments currently in clinical trials, but the process can be long - often taking over a decade before a drug becomes approved and widely available. This process for new drugs is necessary to ensure our safety [...]

Read More

Clinical Trial: BOSTON Trial, Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

The BOSTON trial is a phase 3 study comparing weekly oral selinexor + bortezomib + low-dose dexamethasone (SVd) versus bortezomib (twice weekly) + low-dose dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma. Patients whose myeloma progresses on the Vd arm may be eligible to “cross over” onto the SVd arm. Selinexor is the first in [...]

Read More

Clinical Trials: What are Bispecific Antibodies?

Immunotherapy is a method of treating cancer that uses the body’s immune system to fight the cancer cells. A bispecific antibody is a type of immunotherapy being tested for use in the treatment of Multiple Myeloma. It differs from traditional monoclonal antibodies in that it is engineered to simultaneously target and bind to two [...]

Read More